Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

I Witzel; E Laakmann; R Weide; T Neunhöffer; T-J Park-Simon; M Schmidt; P A Fasching; T Hesse; A Polasik; S Mohrmann; F Würschmidt; C Schem; C Bechtner; R Würstlein; T Fehm; V Möbus; N Burchardi; S Loibl; V Müller

doi:10.1016/j.ejca.2018.07.004

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

Standard

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. / Witzel, I; Laakmann, E; Weide, R; Neunhöffer, T; Park-Simon, T-J; Schmidt, M; Fasching, P A; Hesse, T; Polasik, A; Mohrmann, S; Würschmidt, F; Schem, C; Bechtner, C; Würstlein, R; Fehm, T; Möbus, V; Burchardi, N; Loibl, S; Müller, V.

In: EUR J CANCER, Vol. 102, 10.2018, p. 1-9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Witzel, I, Laakmann, E, Weide, R, Neunhöffer, T, Park-Simon, T-J, Schmidt, M, Fasching, PA, Hesse, T, Polasik, A, Mohrmann, S, Würschmidt, F, Schem, C, Bechtner, C, Würstlein, R, Fehm, T, Möbus, V, Burchardi, N, Loibl, S & Müller, V 2018, 'Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry', EUR J CANCER, vol. 102, pp. 1-9. https://doi.org/10.1016/j.ejca.2018.07.004

APA

Witzel, I., Laakmann, E., Weide, R., Neunhöffer, T., Park-Simon, T-J., Schmidt, M., Fasching, P. A., Hesse, T., Polasik, A., Mohrmann, S., Würschmidt, F., Schem, C., Bechtner, C., Würstlein, R., Fehm, T., Möbus, V., Burchardi, N., Loibl, S., & Müller, V. (2018). Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. EUR J CANCER, 102, 1-9. https://doi.org/10.1016/j.ejca.2018.07.004

Vancouver

Witzel I, Laakmann E, Weide R, Neunhöffer T, Park-Simon T-J, Schmidt M et al. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. EUR J CANCER. 2018 Oct;102:1-9. https://doi.org/10.1016/j.ejca.2018.07.004

Bibtex

@article{80dd48824e3e47ce9b370eece70cbc0a,

title = "Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry",

abstract = "BACKGROUND: Brain metastases (BMs) have a major impact on life expectancy and quality of life for many breast cancer patients. Knowledge about treatment patterns and outcomes is limited.METHODS: We analysed clinical data of 1712 patients diagnosed with BMs from breast cancer between January 2000 and December 2016 at 80 institutions.RESULTS: Median age at diagnosis of BMs was 56 years (22-90 years). About 47.8% (n = 732) of patients had HER2-positive, 21.4% (n = 328) had triple-negative and 30.8% (n = 471) had hormone receptor (HR)-positive, HER2-negative (luminal-like) primary tumours. The proportion of patients with HER2-positive BMs decreased comparing the years 2000-2009 with 2010-2015 (51%-44%), whereas the percentage of patients with luminal-like tumours increased (28%-34%; p = 0.0331). Patients with BMs in the posterior fossa were more often HER2 positive (n = 169/314, 53.8%) than those diagnosed with triple-negative (n = 65/314, 20.7%) or luminal-like primary breast cancer (n = 80/314, 25.5%), (p < 0.0001). Median overall survival (OS) time after development of BMs for the overall cohort was 7.4 months (95% confidence interval [CI]: 6.7-8.0 months). One-year survival rate was 37.7% (95% CI: 35.2-40.1). Patients with HER2-positive tumours had the longest median OS of 11.6 months (95% CI: 10.0-13.4) compared with 5.9 months (95% CI: 5.0-7.2) for patients with luminal-like and 4.6 months (95% CI: 3.9-5.4) for patients with triple-negative tumours. Patients with HER2-positive tumours who received anti-HER2 treatment had longer median OS than those without (17.1 months versus 7.2 months, p < 0.0001).CONCLUSIONS: Prognosis of patients after developing BMs varies significantly according to the subtype. The outcome in this cohort is similarly poor in triple-negative and HR-positive/HER2-negative patients. Our results underline the high medical need for improvement of treatment and prevention strategies for BMs in breast cancer patients.",

keywords = "Journal Article",

author = "I Witzel and E Laakmann and R Weide and T Neunh{\"o}ffer and T-J Park-Simon and M Schmidt and Fasching, {P A} and T Hesse and A Polasik and S Mohrmann and F W{\"u}rschmidt and C Schem and C Bechtner and R W{\"u}rstlein and T Fehm and V M{\"o}bus and N Burchardi and S Loibl and V M{\"u}ller",

year = "2018",

month = oct,

doi = "10.1016/j.ejca.2018.07.004",

language = "English",

volume = "102",

pages = "1--9",

journal = "EUR J CANCER",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

AU - Witzel, I

AU - Laakmann, E

AU - Weide, R

AU - Neunhöffer, T

AU - Park-Simon, T-J

AU - Schmidt, M

AU - Fasching, P A

AU - Hesse, T

AU - Polasik, A

AU - Mohrmann, S

AU - Würschmidt, F

AU - Schem, C

AU - Bechtner, C

AU - Würstlein, R

AU - Fehm, T

AU - Möbus, V

AU - Burchardi, N

AU - Loibl, S

AU - Müller, V

PY - 2018/10

Y1 - 2018/10

N2 - BACKGROUND: Brain metastases (BMs) have a major impact on life expectancy and quality of life for many breast cancer patients. Knowledge about treatment patterns and outcomes is limited.METHODS: We analysed clinical data of 1712 patients diagnosed with BMs from breast cancer between January 2000 and December 2016 at 80 institutions.RESULTS: Median age at diagnosis of BMs was 56 years (22-90 years). About 47.8% (n = 732) of patients had HER2-positive, 21.4% (n = 328) had triple-negative and 30.8% (n = 471) had hormone receptor (HR)-positive, HER2-negative (luminal-like) primary tumours. The proportion of patients with HER2-positive BMs decreased comparing the years 2000-2009 with 2010-2015 (51%-44%), whereas the percentage of patients with luminal-like tumours increased (28%-34%; p = 0.0331). Patients with BMs in the posterior fossa were more often HER2 positive (n = 169/314, 53.8%) than those diagnosed with triple-negative (n = 65/314, 20.7%) or luminal-like primary breast cancer (n = 80/314, 25.5%), (p < 0.0001). Median overall survival (OS) time after development of BMs for the overall cohort was 7.4 months (95% confidence interval [CI]: 6.7-8.0 months). One-year survival rate was 37.7% (95% CI: 35.2-40.1). Patients with HER2-positive tumours had the longest median OS of 11.6 months (95% CI: 10.0-13.4) compared with 5.9 months (95% CI: 5.0-7.2) for patients with luminal-like and 4.6 months (95% CI: 3.9-5.4) for patients with triple-negative tumours. Patients with HER2-positive tumours who received anti-HER2 treatment had longer median OS than those without (17.1 months versus 7.2 months, p < 0.0001).CONCLUSIONS: Prognosis of patients after developing BMs varies significantly according to the subtype. The outcome in this cohort is similarly poor in triple-negative and HR-positive/HER2-negative patients. Our results underline the high medical need for improvement of treatment and prevention strategies for BMs in breast cancer patients.

AB - BACKGROUND: Brain metastases (BMs) have a major impact on life expectancy and quality of life for many breast cancer patients. Knowledge about treatment patterns and outcomes is limited.METHODS: We analysed clinical data of 1712 patients diagnosed with BMs from breast cancer between January 2000 and December 2016 at 80 institutions.RESULTS: Median age at diagnosis of BMs was 56 years (22-90 years). About 47.8% (n = 732) of patients had HER2-positive, 21.4% (n = 328) had triple-negative and 30.8% (n = 471) had hormone receptor (HR)-positive, HER2-negative (luminal-like) primary tumours. The proportion of patients with HER2-positive BMs decreased comparing the years 2000-2009 with 2010-2015 (51%-44%), whereas the percentage of patients with luminal-like tumours increased (28%-34%; p = 0.0331). Patients with BMs in the posterior fossa were more often HER2 positive (n = 169/314, 53.8%) than those diagnosed with triple-negative (n = 65/314, 20.7%) or luminal-like primary breast cancer (n = 80/314, 25.5%), (p < 0.0001). Median overall survival (OS) time after development of BMs for the overall cohort was 7.4 months (95% confidence interval [CI]: 6.7-8.0 months). One-year survival rate was 37.7% (95% CI: 35.2-40.1). Patients with HER2-positive tumours had the longest median OS of 11.6 months (95% CI: 10.0-13.4) compared with 5.9 months (95% CI: 5.0-7.2) for patients with luminal-like and 4.6 months (95% CI: 3.9-5.4) for patients with triple-negative tumours. Patients with HER2-positive tumours who received anti-HER2 treatment had longer median OS than those without (17.1 months versus 7.2 months, p < 0.0001).CONCLUSIONS: Prognosis of patients after developing BMs varies significantly according to the subtype. The outcome in this cohort is similarly poor in triple-negative and HR-positive/HER2-negative patients. Our results underline the high medical need for improvement of treatment and prevention strategies for BMs in breast cancer patients.

KW - Journal Article

U2 - 10.1016/j.ejca.2018.07.004

DO - 10.1016/j.ejca.2018.07.004

M3 - SCORING: Journal article

C2 - 30099223

VL - 102

SP - 1

EP - 9

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

ER -